Suchergebnisse - (Standardsuche:Dexamethasone OR corticosteroid)

1

Clinical and economic review report : indication: Crohn diseaseVedolizumab (ENTYVIO SC) Takeda Canada Inc

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, April 2021

CADTH common drug review

Final (with redactions)

2

Clinical review report : (Novartis Pharmaceuticals Canada Inc.) : indication: asthma maintenance, adultsIndacaterol acetate-glycopyrronium bromide-mometasone furoate (Enerzair Breezhaler)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, January 2021

CADTH common drug review

Version: Final (with redactions).

3

Clinical review report : indication: treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapiesUstekinumab (Stelara/Stelara I.V.) Janssen Inc

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, September 2020

CADTH common drug review

Version: Final (with redactions).

4

Acute treatments for episodic migraine

Erschienen: Rockville, MD, Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, December 2020

Comparative effectiveness review - number 239

von Halker Singh, R.

5

Pharmacoeconomic review report : indication: for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapyIxekizumab (Taltz) (Eli Lilly Canada Inc.)

Erschienen: Ottawa (ON), CADTH, May 2020

CADTH common drug review

Final.

6

Intravitreal dexamethasone implants for non-infectious uveitis : a review of clinical effectiveness, cost-effectiveness, and guidelines

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, March 25, 2020

CADTH rapid response report: summary with critical appraisal

Version: 1.0.

von Yu, C. | MacDougall, D.

7

Clinical review report : (Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.) : indication : indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PEX) and immunosuppressive therapyCaplacizumab (Cablivi)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, October 2020

CADTH common drug review

Final (with redactions).

8

Musculoskeletal injections and alternative options : a practical guide to 'what, when and how?'

Erschienen: Boca Raton, FL, CRC Press, Taylor & Francis Group, [2019]

von Bhatia, M. | Paramesparan, K.

9

Pharmacoeconomic review report : indication: for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate response, loss of response, or intolerance to either conventional UC therapy or a tumour necrosis factor alpha inhibitorTofacitinib (Xeljanz) (Pfizer Canada Inc.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, March 2019

CADTH common drug review

Version: Final.

10

Aerobic exercise for chronic non-cancer back pain : a review of clinical effectiveness

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, October 16, 2019

CADTH rapid response report: summary with critical appraisal

Version: 1.0.

von Banerjee, S. | Walter, M.

Filter & Sortierung